Merck's Phase 3 KEYNOTE-A18 Trial Of Keytruda + External Beam Radiotherapy + Concurrent Chemotherapy, Followed By Brachytherapy Met Primary Endpoints Of Progression-free Survival In Newly Diagnosed Patients With High-risk Locally Advanced Cervical Cancer
Portfolio Pulse from Benzinga Newsdesk
Merck's Phase 3 KEYNOTE-A18 trial of Keytruda, in combination with external beam radiotherapy and concurrent chemotherapy, followed by brachytherapy, has met its primary endpoints of progression-free survival in newly diagnosed patients with high-risk locally advanced cervical cancer.
July 19, 2023 | 10:48 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck's successful Phase 3 trial of Keytruda could potentially lead to increased demand for the drug, positively impacting Merck's stock.
The successful trial results indicate that Keytruda is effective in treating high-risk locally advanced cervical cancer. This could lead to increased demand for the drug, which would likely result in increased revenues for Merck, potentially leading to a positive impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100